| Literature DB >> 28860766 |
Sameh Samir Ali1,2, Reda Morsy3,4, Nessma Ahmed El-Zawawy2, Mervat F Fareed5,6, Mohamed Yaser Bedaiwy2.
Abstract
Increasing of multidrug resistance (MDR) remains an intractable challenge for burnEntities:
Keywords: anti-inflammatory; antimicrobial; burn wound infections; co-precipitation method; metal oxides nanoparticles; multidrug resistance
Mesh:
Substances:
Year: 2017 PMID: 28860766 PMCID: PMC5573044 DOI: 10.2147/IJN.S141201
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Antimicrobial activity of ZnO2-NPs against MDR Pseudomonas aeruginosa and Aspergillus niger strains
| Strain number | Diameter of inhibition zone (mm)
| MIC | MBC | MFC | AMP | ||
|---|---|---|---|---|---|---|---|
| Concentrations of ZnO2-NPs (µg/mL)
| |||||||
| 50 | 100 | 200 | |||||
| PA1 | 7.0±0.0a | 7.0±0.0a | 8.0±0.0a | 50 | 100 | ND | AX, CTX, CAZ, CRO, ATM, SXT, TE, C, K, CT |
| PA2 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | ND | ND | ND | AX, CTX, CAZ, FEP, CRO, ATM, CIP, SXT, TE, C, TOB, K |
| PA3 | 9.0±1.0c | 10.0±1.0c | 11.0±1.0c | 50 | 100 | ND | AX, CTX, CAZ, ATM, CIP, SXT, TE, C, K, CT |
| PA4 | 7.0±1.0a | 12.0±0.0d | 15.0±2.0d | 25 | 50 | ND | AX, CAZ, FEP, CRO, CIP, SXT, CN, TOB, K, CT |
| PA5 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | ND | ND | ND | AX, CTX, CAZ, FEP, CRO, CIP, SXT, TE, K |
| PA6 | 12.0±2.0d | 17.0±2.0e | 21.0±1.0e | 6.25 | 12.5 | ND | AX, CTX, CAZ, CRO, ATM, CIP, SXT, TE, CN, TOB, K, CT |
| PA7 | 9.0±0.0c | 13.0±0.0d | 18.0±0.0f | 6.25 | 12.5 | ND | AX, CTX, CAZ, CRO, ATM, IPM, SXT, TE, C, TOB, CT |
| PA8 | 10.0±1.0e | 11.0±1.0d | 15.0±1.0d | 25 | 50 | ND | AX, CTX, CAZ, FEP, CRO, ATM, CIP, SXT, C, K, CT |
| PA9 | 7.0±0.0a | 9.0±0.0f | 12.0±0.0c | 50 | 100 | ND | AX, CAZ, FEP, ATM, CRO, IPM, CIP, SXT, C, CN, TOB, K, CT |
| PA10 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | ND | ND | ND | AX, CTX, CAZ, FEP, ATM, CIP, SXT, TE, C, CN, TOB, K, CT |
| PA11 | 0.0±0.0b | 7.0±0.0a | 10.0±1.0c | 50 | 100 | ND | AX, CTX, CAZ, FEP, CRO, ATM, CIP, SXT, TE, TOB, K, CT |
| AN1 | 20.0±2.0f | 25.0±1.0g | 35.0±3.0g | 6.25 | ND | 12.5 | ITC, MIZ, FLC, NYT, TRB |
| AN2 | 10.0±0.0e | 16.0±1.0e | 22.0±2.0e | 12.5 | ND | 25 | ITC, CLT, FLC, MCFG, TRB |
| AN3 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | 0.0 | ND | ND | AMB, ITC, MIZ, FLC, MCFG, TRB |
| AN4 | 30.0±3.0g | 30.0±3.0h | 40.0±1.0h | 6.25 | ND | 12.5 | ITC, CLT, FLC, MCFG, NYT, TRB |
| AN5 | 20.0±2.0f | 25.0±2.0g | 30.0±2.0i | 6.25 | ND | 12.5 | AMB, ITC, CLT, MIZ, FLC, TRB |
| AN6 | 11.0±0.0h | 11.0±0.0d | 18.0±0.0f | 25 | ND | 50 | ITC, CLT, MIZ, FLC, NYT, TRB |
| AN7 | 14.0±2.0i | 20.0±1.0i | 25.0±1.0j | 6.25 | ND | 12.5 | AMB, ITC, CLT, FLC, MCFG, NYT, TRB |
| AN8 | 9.0±0.0c | 16.0±1.0e | 20.0±0.0e | 25 | ND | 50 | AMB, ITC, MIZ, FLC, TRB |
| AN9 | 18.0±2.0j | 22.0±2.0i | 32.0±2.0g,i | 6.25 | ND | 12.5 | ITC, CLT, MIZ, FLC, MCFG, TRB |
| AN10 | 14.0±1.0i | 20.0±1.0i | 28.0±1.0j | 25 | ND | 50 | AMB, ITC, CLT, MIZ, FLC, NYT, TRB |
| AN11 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | 0.0 | ND | ND | ITC, CLT, FLC, MCFG, NYT, TRB |
| ANOVA | |||||||
| F | 0.133 | 0.0349 | 0.001 | ||||
| | 0.875 | 0.965 | 0.998 | ||||
Notes: Values are the mean of three replicates ± SD. Means with the same letters in the same column show the insignificant difference (P≤0.05).
Abbreviations: AMB, amphotericin; AMP, antimicrobial profile; AN, Aspergillus niger; ANOVA, analysis of variance; ATM, aztreonam; AX, amoxicillin; C, chloramphenicol; CAZ, ceftazidime; CIP, ciprofloxacin; CLT, clotrimazole; CN, gentamicin; CRO, ceftriaxone; CT, colistin sulfate; CTX, cefotaxime; FEP, cefepime; FLC, fluconazole; IPM, imipenem; ITC, itraconazole; K, kanamycin; MBC, minimum bactericidal concentration; MCFG, micfungin; MDR, multidrug resistance; MFC, minimum fungicidal concentration; MIC, minimum inhibitory concentration; MIZ, miconazole; NPs, nanoparticles; ND, not detected; NYT, nystatin; PA, Pseudomonas aeruginosa; SXT, cotrimoxazole; TE, tetracycline; TOB, tobramycin; TRB, terbinafine.
Figure 1X-ray diffraction pattern of the synthetic ZnO2-NPs.
Figure 2Fourier transformed infrared spectrum of the synthetic ZnO2-NPs.
Figure 3Transmission electron microscopy image of the synthetic ZnO2-NPs.
Figure 4Thermogravimetric analysis and differential scanning calorimetric curves of the synthetic ZnO2-NPs.
Figure 5Ultraviolet spectra of the synthetic ZnO2-NPs.
Figure 6Time course of elastase (A) and keratinase (B) production by PA6 strain (blue line) and AN4 strain (red line).
Abbreviations: AN, Aspergillus niger; PA, Pseudomonas aeruginosa.
Anti-elastase and anti-keratinase activities of ZnO2-NPs
| Concentration of ZnO2-NPs (µg/mL) | Enzyme activity (U/mL)
| |||
|---|---|---|---|---|
| Elastase
| Keratinase
| |||
| PA6 | AN4 | PA6 | AN4 | |
| 6.25 | 28.0±1.0a | 31.0±1.0a | 25.0±1.0a | 37.0±2.0a |
| 12.5 | 23.0±2.0b | 21.0±1.0b | 13.0±1.0b | 35.0±1.0b |
| 25 | 18.0±1.0c | 14.0±0.0c | 9.0±0.0c | 26.0±0.0c |
| 50 | 6.0±0.0d | 8.0±0.0d | 5.0±0.0d | 20.0±1.0d |
| 100 | 1.0±0.0e | 2.0±0.0e | 0.0±0.0e | 12.0±0.0e |
| 200 | 0.0±0.0f | 0.0±0.0f | 0.0±0.0e | 0.0±0.0e |
| ANOVA | ||||
| F | 0.002 | 0.001 | 0.002 | 0.007 |
| | 0.997 | 0.998 | 0.997 | 0.992 |
Notes: Values are the mean of three replicates ± SD. Means with the same letters in the same column showed the insignificant difference (P≤0.05).
Abbreviations: AN, Aspergillus niger; ANOVA, analysis of variance; NPs, nanoparticles; PA, Pseudomonas aeruginosa.
Anti-inflammatory effect of ZnO2-NPs compared to aspirin
| Concentration (µg/mL) | Inhibitory percentage of albumin denaturation
| Percentage of membrane stabilization activity
| Inhibitory percentage of proteinase activity
| |||
|---|---|---|---|---|---|---|
| ZnO2-NPs | Aspirin | ZnO2-NPs | Aspirin | ZnO2-NPs | Aspirin | |
| 100 | 25.0±0.0a | 40.1±0.7a | 28.0±1.0a | 42.3±1.1a | 30.0±0a | 58.0±1.0a |
| 250 | 40.0±2.0b | 41.7±1.1a,b | 45.0±1.0b | 68.6±1.5b | 47.0±2b | 68.7±2.2b |
| 500 | 57.0±3.0c | 45.7±2.5b | 62.0±2.0c | 71.3±2.0b | 58.0±2c | 81.5±0.5c |
| 1,000 | 82.0±1.0d | 71.1±1.0c | 73.0±1.0d | 74.9±0.5b,c | 80.0±1d | 83.7±0.4c |
| 2,000 | 90.0±3.0d | 85.3±2.1d | 81.0±3.0e | 82.1±2.2c | 89.0±2e | 89.2±1.9c |
| ANOVA | ||||||
| F | 0.0008 | 0.0004 | 0.0156 | 0.045 | 0.0003 | 0.0193 |
| | 0.9991 | 0.9995 | 0.9845 | 0.9561 | 0.9996 | 0.9808 |
Notes: Values are the mean of three replicates ± SD. Means with the same letters in the same column showed the insignificant difference (P≤0.05).
Abbreviations: ANOVA, analysis of variance; NPs, nanoparticles.
Figure 7Histopathological examination of burn wounds after 7 days (A, C) and 21 days (B, D) after treatment protocols with ZnO2-NPs (A, B) compared to silver sulfadiazine (C, D).
Note: Magnification power (200×).
Abbreviation: NPs, nanoparticles.
In vivo evaluation of inflammation, ulcer formation, and re-epithelialization in different rabbit groups
| Rabbit group (n=6) | Inflammation | Surface ulceration | Re-epithelialization |
|---|---|---|---|
| Group 1 (negative control) | + | + | Partial |
| Group 2 (positive control) | + | + | − |
| Group 3 (ZnO2-NPs-receiving group) | − | − | Complete |
| Group 4 (silver sulfadiazine-receiving group) | + | + | − |
Notes: −, absent; +, present.
Abbreviation: NPs, nanoparticles.